Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through

Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through Inhibitor of Apoptosis Protein Antagonism

ReachMD Healthcare Image
RestartResume

Hear about emerging trial data demonstrating that an IAP antagonist can improve overall survival in patients with LA SCCHN treated with CRT.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:

    Kevin Harrington, BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC
    Head of Division of Radiotherapy and Imaging
    The Institute of Cancer Research
    London, UK

    Consulting Fees: Amgen, Arch Oncology, Artios Pharma, AstraZeneca, BMS, Boehringer Ingelheim, Codiak BioSciences, Idera Pharmaceuticals, Merck, Merck Sharp & Dohme, Oncolys, Pfizer, PsiVac, Replimune, and Vyriad.

    Faculty:

    Barbara Burtness, MD
    Professor of Medicine
    Co-Leader, Developmental Therapeutics Program
    Interim Associate Director, Diversity, Equity and Inclusion
    Yale Cancer Center, Yale School of Medicine
    New Haven, CT

    Consulting Fees: ALX Oncology, AstraZeneca, Cue Biopharma, DeBio, Genentech, Hookipa, IO Biotech, Kura, MacroGenics, Merck, Merck KGaA, Nanobiotix, Nektar, and Nuvelution

    Ari Rosenberg, MD
    Assistant Professor and Medical Oncologist,
    University of Chicago Medicine
    Chicago, IL

    No relevant relationships reported.

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Differentiate the mechanisms of action of agents currently being investigated for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) from those of currently available treatment options
    • Assess the therapeutic potential of agents being investigated for the management of LA SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, radiation oncologists, and other healthcare professionals treating patients with head and neck cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     

    Global Learning Collaborative (GLC) designates this Podcast PLUS activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free